Assertio Therapeutics Inc
Assertio Holdings, Inc., a pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provid… Read more
Assertio Therapeutics Inc (ASRT) - Total Assets
Latest total assets as of September 2025: $319.77 Million USD
Based on the latest financial reports, Assertio Therapeutics Inc (ASRT) holds total assets worth $319.77 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Assertio Therapeutics Inc - Total Assets Trend (1996–2024)
This chart illustrates how Assertio Therapeutics Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Assertio Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Assertio Therapeutics Inc's total assets of $319.77 Million consist of 71.1% current assets and 28.9% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 17.8% |
| Accounts Receivable | $54.12 Million | 19.0% |
| Inventory | $38.31 Million | 13.5% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $80.47 Million | 28.3% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (1996–2024)
This chart illustrates how Assertio Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Assertio Therapeutics Inc's current assets represent 71.1% of total assets in 2024, an increase from 66.7% in 1996.
- Cash Position: Cash and equivalents constituted 17.8% of total assets in 2024, up from 0.0% in 1996.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 28.0% of total assets, an increase from 0.0% in 1996.
- Asset Diversification: The largest asset category is intangible assets at 28.3% of total assets.
Assertio Therapeutics Inc Competitors by Total Assets
Key competitors of Assertio Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biostar Pharmaceuticals Inc
PINK:BSPM
|
USA | $41.43 Million |
|
High Sierra Technologies Inc
PINK:HSTI
|
USA | $10.70K |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423
|
China | CN¥12.75 Billion |
Assertio Therapeutics Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Assertio Therapeutics Inc generates 0.44x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Assertio Therapeutics Inc is currently not profitable relative to its asset base.
Assertio Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.58 | 2.01 | 0.71 |
| Quick Ratio | 1.43 | 1.57 | 0.62 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $96.79 Million | $ 91.05 Million | $ -38.43 Million |
Assertio Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Assertio Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.74 |
| Latest Market Cap to Assets Ratio | 0.27 |
| Asset Growth Rate (YoY) | -0.6% |
| Total Assets | $284.73 Million |
| Market Capitalization | $78.11 Million USD |
Valuation Analysis
Below Book Valuation: The market values Assertio Therapeutics Inc's assets below their book value (0.27 x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Assertio Therapeutics Inc's assets decreased by 0.6% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Assertio Therapeutics Inc (1996–2024)
The table below shows the annual total assets of Assertio Therapeutics Inc from 1996 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $284.73 Million | -0.59% |
| 2023-12-31 | $286.42 Million | -30.80% |
| 2022-12-31 | $413.91 Million | +26.75% |
| 2021-12-31 | $326.55 Million | +7.67% |
| 2020-12-31 | $303.27 Million | -42.47% |
| 2019-12-31 | $527.17 Million | -43.49% |
| 2018-12-31 | $932.87 Million | -10.18% |
| 2017-12-31 | $1.04 Billion | -15.24% |
| 2016-12-31 | $1.23 Billion | -10.13% |
| 2015-12-31 | $1.36 Billion | +91.75% |
| 2014-12-31 | $711.07 Million | +39.79% |
| 2013-12-31 | $508.65 Million | +259.08% |
| 2012-12-31 | $141.65 Million | -13.82% |
| 2011-12-31 | $164.37 Million | +88.87% |
| 2010-12-31 | $87.03 Million | -4.97% |
| 2009-12-31 | $91.58 Million | -3.68% |
| 2008-12-31 | $95.08 Million | +17.90% |
| 2007-12-31 | $80.64 Million | +53.27% |
| 2006-12-31 | $52.62 Million | -20.73% |
| 2005-12-31 | $66.38 Million | +190.26% |
| 2004-12-31 | $22.87 Million | -52.05% |
| 2003-12-31 | $47.69 Million | +105.76% |
| 2002-12-31 | $23.18 Million | +165.00% |
| 2001-12-31 | $8.75 Million | +0.16% |
| 2000-12-31 | $8.73 Million | -61.08% |
| 1999-12-31 | $22.43 Million | +117.81% |
| 1998-12-31 | $10.30 Million | +123.91% |
| 1997-12-31 | $4.60 Million | +1433.33% |
| 1996-12-31 | $300.00K | -- |